Principal Nate Manley was interviewed by Insights Bio this month for a Cell and Gene Therapy Insights raw and starting materials spotlight article entitled, “Emerging trends in control and regulation of immunotherapy cellular starting materials.”
Read the full article, including …
published 16 Mar 2021 at written by Amanda Micklusreproduced with permissionoriginal article, herePDF available for download, here
Regenerative medicines have made significant …
CEO Anthony Davies had the distinct honor of being on the panel for the inaugural episode of Phacilitate: Talks, a socially-distanced podcast for the Cell & Gene Therapy space. Click on the image to be taken out to the podcast …
As founder of cell and gene therapy (CGT) specialist firm Dark Horse Consulting Group in California, Anthony Davies speaks from a quarter …
Phacilitate’s Portfolio Director Michael Adeniya shares insights from his call with Dark Horse’s CEO Anthony Davies as he encourages the industry to continue innovating and adapting. Click here for Michael’s message.…
In this Feb 2020 bioprocessintl.com article (click here), Dan Stanton talks to Dark Horse CEO Anthony Davies about what pattern Catalent’s $315M acquisition of Masthercell might be foreshadowing.…
By Nathan Manley & Katy Spink
The cell therapy field is currently in an exciting era of expansion, with a large number of candidate therapies advancing into clinical testing and many more progressing through preclinical pipelines. As the number of …
by Gareth Macdonald
The cell therapy sector faces a cost of goods sold (COGS) crisis and needs to get beyond the “product is the process” mind-set says Anthony Davies, CEO of Dark Horse Consulting.
Cell and gene therapies have attracted …
by Dan Stanton
Fully closed and automated platforms are key to reducing the current high costs of cell and gene therapy manufacturing, say industry experts.
Cell and gene therapies (CGTs) have come a long way over the past two years, …
by Dan Stanton
This is the first time in history that we can make more effective medicines than we can afford, says Dark Horse Consulting.
The Phacilitate conference took place in Miami this week, and in the plenary session Anthony …
by Dan Stanton
The US FDA predicts it will receive more than 200 regenerative INDs per year from 2020 and will add 50 additional staff to review these products.
There has been “a large upswing in the number of investigational …
by Katy Spink & Andrew Steinsapir
With the 2017 FDA approvals and launches of the first gene-modified cell and pure-play gene therapy products to gain licensure in the United States, increasing attention has been paid to the high cost of …
Photo credit Anita Barcsa Photography
©2020 Dark Horse Consulting Group, Inc.
